Silymarin as a potential hypocholesterolaemic drug
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
9708694
Knihovny.cz E-resources
- MeSH
- Anticholesteremic Agents pharmacology MeSH
- Biological Availability MeSH
- Enzyme Inhibitors pharmacology MeSH
- Liver physiology MeSH
- Humans MeSH
- Lipids blood MeSH
- Lipoproteins blood metabolism MeSH
- Lipid Metabolism MeSH
- Peroxidases antagonists & inhibitors MeSH
- Silymarin pharmacokinetics pharmacology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Anticholesteremic Agents MeSH
- Enzyme Inhibitors MeSH
- Lipids MeSH
- Lipoproteins MeSH
- Peroxidases MeSH
- Silymarin MeSH
Silymarin, a mixture of flavonolignans from medicinal plant Silybum marianum, is used in supportive treatment of liver diseases of different etiology due to its hepatoprotective activity, which is considered to involve antioxidative and the membrane stabilizing effects. The liver plays an important role in regulation of metabolism of plasma lipoproteins, and liver injury is often reflected as a secondary dyslipoproteinaemia, which may lead to the development of atherosclerosis, particularly when associated with hypercholesterolaemia. This review summarizes the experimental evidence indicating that silymarin-induced protection of liver functions may be of benefit with regard to liver lipid metabolism related to the regulation of plasma lipoproteins. Moreover, some data suggest that silymarin could have a direct effect on liver cholesterol metabolism by inhibiting cholesterol biosynthesis. It is proposed that silymarin deserves to be studied as a potential hypocholesterolaemic agent.
Chirality Matters: Biological Activity of Optically Pure Silybin and Its Congeners
Biotransformation of Silymarin Flavonolignans by Human Fecal Microbiota